Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

This study uses \[11C\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \[11C\]NOP-1A VT measured at baseline in the midbrain. \[11C\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)

Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Rajesh NarendranUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Males or females between 18 and 55 years old [+12]

Status: Recruiting

Imaging CRF X NOP Interactions in CUD

This study uses \[11C\]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.

Participants needed: 80
Trial details
Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Rajesh NarendranUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Males or females between 18 and 55 years old [+11]

Status: Recruiting

Imaging CRF X NOP Interactions in Alcohol Use Disorder

This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.

Participants needed: 90
Trial details
Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Rajesh NarendranUpdated: Jun 3, 2026Locations: 1
Eligibility criteria

Males or females between 18 and 55 years old [+17]